Listed Chinese medicine enterprise profit TOP20 new change: "three in three out"

Pharmaceutical Network Market Analysis Recently, the Chinese Traditional Medicine Association held a meeting to summarize the performance of listed companies in Chinese medicine manufacturing in 2019Data show that in 2019, 60 Chinese medicine manufacturing listed enterprises achieved a total operating income of 305.45 billion yuan, up 11.47 percent year-on-year, of which Tongrentang, Baiyunshan and other 7 companies revenue of more than 10 billion, the same number as last yearOf the 60 companies, 19 saw revenues fall, accounting for 31.7 per cent, and eight saw their speeds drop by more than 10 per cent.
Total industry profits in 2019 were RMB22.5 billion, down 20.22% from RMB28.2 billion a year earlier, and the average net profit margin fell from 10.29% to 7.37%Of the 60 listed Chinese medicine companies, seven made annual profits of more than 1 billion yuan, two fewer than the previous yearIn addition, the total profit increased by only 31, only half.
According to the ranking of the top 20 companies in profit, Yunnan White Pharmaceutical ranked first with a net profit of 4.18 billion yuan, with net profit increasing by 19.75 percent year-on-year in 2019The 2019 ranking also changed relatively much compared with the previous year, mainly reflected in the "three into three out": Red Day Pharmaceuticals, Shenwei Pharmaceuticals and Guilin Sanjin 3 enterprises newly entered the top 20, Dong'a gu, Kang Enbei and Guizhou Bailing exit.
Among the enterprises newly entered with 2019 net profit TOP20, Red Day Pharmaceuticals' net profit in 2019 was 403 million, up 90.96 percent year-on-yearIt is understood that 2019 is the company's next ten years of development of the "planning year", the reporting period, the red day pharmaceutical companies to lead the company's strategy, adhere to business performance-oriented, scientific decision-making as a guarantee, professional capacity as a tool, system construction as the fundamental, the operating indicators are achieved as planned.
Data show that Red Day Pharmaceuticals focuses on the field of severe diseases, tumors and immunity, cardiovascular, respiratory, neurodegenerative diseases research, through the drug source base, innovative research and development, intelligent manufacturing, sales circulation, intelligent logistics, multi-dimensional terminal of the large health of the whole industrial chain.
Shenwei Pharmaceuticals' business covers the research and development, production, sales, e-commerce and formulation particles and other fieldsNet profit in 2019 was RMB503 million, down 0.5% from 19 years agoAccording to the company's annual report, the increase in turnover during the year was mainly due to Chinese medicine formula particles, softgel products and other oral productsThe total annual net profit was reduced by 0.5% over the previous year, resulting from a one-time impairment expenditure of 36 million due to the termination of a research and development project, together with the provision for impairment provisions required by international accounting standards for a risk assessment of bank deposits and trade receivablesNet income was revised down to 18.6 percent from 19.7 percent, but earnings per share rose 3.2 percent from a year earlier to 64 centsWithout the above impairment expenses and provisions, full-year net profit would have been 8.3% higher than the previous year.
Guilin Sanjin achieved a net profit of 392 million yuan, down 5.13% Year-on-yearGuilin Sanjin is located in the pharmaceutical manufacturing industry, the company's main business for the research and development of traditional Chinese medicine research and development, manufacturing and sales, while covering chemical preparations, biologics and daily health care and other sub-sectors.
In addition, among the top 20 companies, Dong'a Gum and Cornbey lost 444 million yuan and 346 million yuan in net profit in 2019, respectively, while Guizhou Bailing's net profit in 2019 was 291 million yuan, down 48.27 percent year-on-year.
Industry sources said that by analyzing the development trend of 60 enterprises in recent years, especially the actual performance of the top 20 companies, we can find that the concentration of the Chinese medicine industry in recent years has increased significantly, the total proportion of these 60 listed companies in the Chinese medicine industry is increasingEntering 2020, with the promotion of good policies of Chinese medicine, the industry may usher in the spring of development, a new round of competition between enterprises will also be opened.